International Clinical Trial: A Prospective, Exploratory Study of Lurbinectedin combined with Atezolizumab with or without Anlotinib as Second-line Therapy for Extensive-Stage Small Cell Lung Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132081) titled 'A Prospective, Exploratory Study of Lurbinectedin combined with Atezolizumab with or without Anlotinib as Second-line Therapy for Extensive-Stage Small Cell Lung Cancer' on Sept. 9.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital,Sun Yat-sen University

Condition: Small Cell Lung Cancer

Intervention: Experimental group:lurbinectedin combined with atezolizumab with anlotinib

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-20

Target Sample Size: Experimental group:20;Control group:20;

Countries of Recruitment: Chi...